During the question-and-answer session following the presentation, Dr. Andrew D. Zelenetz from Memorial Sloan-Kettering Cancer Center in New York challenged Dr. Hermine to explain why the group broadly recommended the adoption of R-CHOP/R-DHAP plus high-dose cytarabine for all younger patients with MCL, given the strict inclusion criteria of the study.
Dr. Hermine agreed that the regimen might best be reserved for higher risk patients (International Prognostic Index score higher than 1), while lower-risk patients could benefit from the standard R-CHOP regimen.
Dr. Hermine and coauthors said they had no relevant conflicts of interest.